BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Xiao J, Zhang Y. AURKB as a Promising Prognostic Biomarker in Hepatocellular Carcinoma. Evol Bioinform Online 2021;17:11769343211057589. [PMID: 34866894 DOI: 10.1177/11769343211057589] [Reference Citation Analysis]
2 Zhu J, Zhou Y, Wang L, Hao J, Chen R, Liu L, Li J. CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma. J Gastrointest Oncol 2020;11:1364-80. [PMID: 33457007 DOI: 10.21037/jgo-20-556] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Wang R, Lin N, Mao B, Wu Q. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. J Cancer Res Clin Oncol 2021. [PMID: 34297207 DOI: 10.1007/s00432-021-03716-1] [Reference Citation Analysis]
4 Alshehri MA, Alshehri MM, Albalawi NN, Al-Ghamdi MA, Al-Gayyar MMH. Heparan sulfate proteoglycans and their modification as promising anticancer targets in hepatocellular carcinoma. Oncol Lett 2021;21:173. [PMID: 33552290 DOI: 10.3892/ol.2021.12434] [Reference Citation Analysis]